Results 151 to 160 of about 2,566,443 (193)

Determinants of Achieving Serum Urate Goal with Treat-to-Target Urate-Lowering Therapy in Gout. [PDF]

Arthritis Rheumatol
Helget LN, O'Dell JR, Newcomb JA, Androsenko M, Brophy MT, Davis-Karim A, England BR, Ferguson R, Pillinger MH, Neogi T, Palevsky PM, Wu H, Kramer B, Mikuls TR.   +13 more
europepmc   +1 more source

Urate-lowering therapy, serum urate, inflammatory biomarkers, and renal function in patients with gout following pegloticase discontinuation. [PDF]

Arthritis Res Ther
Holladay EE, Mudano AS, Xie F, Zhang J, Mikuls TR, LaMoreaux B, Padnick-Silver L, Curtis JR.   +7 more
europepmc   +1 more source

Identifying the association between serum urate levels and gout flares in patients taking urate-lowering therapy: a post hoc cohort analysis of the CARES trial with consideration of dropout. [PDF]

Ann Rheum Dis
Tedeschi SK, Hayashi K, Zhang Y, Choi H, Solomon DH.   +4 more
europepmc   +1 more source

Erratum: Quantitative Assessment of Baseline Serum HDL-C to Predict Gout Flares During Urate-Lowering Therapy Initiation: A Prospective Cohort Study [Corrigendum]. [PDF]

J Inflamm Res
europepmc   +1 more source

Correction to: Non-adherence to urate lowering therapy in gout after 5 years is related to poor outcomes: results from the NOR-Gout study. [PDF]

Rheumatology (Oxford)
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Expert opinion on emerging urate-lowering therapies

Expert Opinion on Emerging Drugs, 2018
There has been a resurgence in gout therapeutics in the last decade, not only for the management of gout flares, but also for the treatment of hyperuricemia. This editorial summarizes new, emerging therapies for people with gout. Areas covered: We review several new therapies for gout, including those that are focused on lowering serum urate ...
Lisa Stamp, Tony Merriman, Jasvinder Singh   +2 more
exaly   +3 more sources

Cardiovascular Safety of Urate Lowering Therapies

Current Rheumatology Reports, 2019
The effect of urate lowering treatment (ULT) on cardiovascular (CV) risk and mortality in gout has been a topic of interest. This review discusses the CV effect of ULT and comparative CV safety among ULT agents.The mechanism linking gout with CV risk is not fully understood but seems multifactorial involving hyperuricemia, xanthine oxidase (XO ...
Eun Ha, Kang, Seoyoung C, Kim
openaire   +2 more sources

Update on emerging urate-lowering therapies

Current Opinion in Rheumatology, 2009
To discuss currently available urate-lowering therapeutic options for gout in the United States and newer therapeutic initiatives in development.Currently available urate-lowering drugs include allopurinol and probenecid. These drugs are effective but are often underdosed or underutilized, and caution must be taken in patients with multiple ...
Saima, Chohan, Michael A, Becker
openaire   +2 more sources

Urate‐Lowering Therapy for Gout: Focus on Febuxostat

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2010
Gout is a common, painful, and often debilitating rheumatologic disorder that remains one of the few arthritic conditions that can be diagnosed with certainty and cured with appropriate therapy. Allopurinol is the most frequently prescribed agent for gout in the United States.
Bryan L, Love, Robert, Barrons, Angie, Veverka, K Matthew, Snider   +3 more
openaire   +2 more sources

Potential Dangers of Serum Urate-Lowering Therapy

The American Journal of Medicine, 2019
In observational studies, high serum urate levels are associated with adverse outcomes, including mortality. However, the hypothesis that urate-lowering may improve nongout outcomes has not been confirmed by placebo-controlled clinical trials. On the contrary, 7 recent placebo-controlled trials of urate-lowering drugs with different mechanisms of ...
Maria Vanessa Perez-Gomez, Lorenz-Alexander Bartsch, Esmeralda Castillo-Rodriguez, Raul Fernandez-Prado, Mehmet Kanbay, Alberto Ortiz   +5 more
openaire   +2 more sources